Final Analysis of the Phase 1/2 Trial of Valoctocogene Roxaparvovec for Severe Haemophilia A
P Raheja, Savita Rangarajan, Will Lester, Bella Madan et autres
gb, us (code pays fourni par la source)
0 citations
Haemophilia
Emily Symington
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
38Publications signalées
2179Citations signalées
1Affiliations récentes
Les institutions déclarées
Les domaines associés
Hemophilia Treatment and ResearchVirus-based gene therapy researchBlood Coagulation and Thrombosis MechanismsPlatelet Disorders and TreatmentsVenous Thromboembolism Diagnosis and Management
Les publications récentes
Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results
Andrew D. Leavitt, Johnny Mahlangu, Priyanka Raheja, Emily Symington et autres
us, Afrique du Sud, gb, il, tw, de, au, fr, it, br (code pays fourni par la source)
2 citations
Research and Practice in Thrombosis and Haemostasis
Future-Proofing Chocolate: The Environmental Resilience of Cacao Wild Relatives
Emily Symington, James Richardson, Peter W. Moonlight
ie (code pays fourni par la source)
0 citations
Biodiversity Information Science and Standards
The Role of Healthy Relationships and Social Connectivity in the Mediterranean Lifestyle: An Umbrella Review of Reviews
Gulnur Yaman‐Dent, Gloria Dent, Rob Lawson, Hannah Maycroft et autres
us, gb, cy, nl (code pays fourni par la source)
2 citations
Lifestyle Medicine
Group Consultations and Community-Integrated Care
Emily Symington, Fraser Birrell
0 citations
Cambridge University Press eBooks
Efficacy and safety of valoctocogene roxaparvovec 4 years after gene transfer in GENEr8-1
Andrew D. Leavitt, Johnny Mahlangu, Priyanka Raheja, Emily Symington et autres
us, Afrique du Sud, gb, il, tw, de, au, fr, it, br (code pays fourni par la source)
1 citation
Hämostaseologie
Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial
Margareth C. Ozelo, Bella Madan, Flora Peyvandi, Dominic Pepperell et autres
us (code pays fourni par la source)
0 citations
Carolina Digital Repository (University of North Carolina at Chapel Hill)
Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial
Andrew D. Leavitt, Johnny Mahlangu, Priyanka Raheja, Emily Symington et autres
us, Afrique du Sud, gb, es, il, tw, de, au, fr, it, br (code pays fourni par la source)
45 citations
Research and Practice in Thrombosis and Haemostasis
Valoctocogene roxaparvovec gene therapy provides durable haemostatic control for up to 7 years for haemophilia A
Emily Symington, Savita Rangarajan, Will Lester, Bella Madan et autres
gb, us (code pays fourni par la source)
37 citations
Haemophilia
Long‐term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post‐treatment
Emily Symington, Savita Rangarajan, Will Lester, Bella Madan et autres
gb, us (code pays fourni par la source)
48 citations
Haemophilia
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
Steven W. Pipe, Frank W.G. Leebeek, Michael Recht, Nigel S. Key et autres
us, nl, de, dk, ie, gb, se, be (code pays fourni par la source)
364 citations
New England Journal of Medicine
Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A
Johnny Mahlangu, Radosław Kaczmarek, Annette von Drygalski, Susan Shapiro et autres
Afrique du Sud, us, pl, gb, tw, br, il, it, au, de, fr (code pays fourni par la source)
200 citations
New England Journal of Medicine
BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.